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Abstract
Background: Despite the World Health Organization and the National Malaria Program of Madagascar recommending
that antimalarial drugs only be prescribed for patients with positive results on malaria rapid diagnostic tests, healthcare
workers continue to prescribe these drugs for cases with negative test results. We explored why and how primary
healthcare workers in Madagascar continue to prescribe antimalarial drugs despite this guidance.
Methods: We purposively selected 14 medical doctors and 2 nurses from 11 primary health facilities (6 public, 5 private) in
Toliara, Madagascar, and interviewed them regarding their antimalarial prescribing behaviors. Semi-structured interviews
were conducted, focusing on why and how antimalarials were prescribed for clients with negative rapid diagnostic test
results. Interviews were audio-recorded and transcribed verbatim, and the responses were manually coded until consistent
themes emerged.
Results: The narrative of healthcare workers regarding their continued prescribing of antimalarials despite negative test
results revealed the following: (1) they prescribe antimalarials without positive test results due to their faith to give top
priority to clients including the ethical value of beneficence, hope to maintain clinician’s independence, and belief in drug
effectiveness; (2) they use antimalarials despite negative test results due to the availability of alternative ways to procure
antimalarials; and (3) they carefully select cases to prescribe and determine specific antimalarials despite negative test results
by considering the client’s physical condition, preference, and economic status. Our results indicate that healthcare workers
prioritized clinician autonomy to give the best care they believed for each client they received, which led to conflict with
policy administrators that urged clinicians to follow the national policy and guidelines. Moreover, healthcare workers had
access to multiple sources of antimalarial drugs, and there was a lack of consistency in the program provisions that allowed
alternative routes for prescribing outside of official policy.
Conclusions: We have shown how a national malarial treatment policy was translated into practice in Madagascar and
have highlighted the barriers that may prevent policy success. We must attend to each of these barriers if we are to
promote optimal use of antimalarial drugs.
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Background
Parasitological malaria diagnosis, using either a rapid diag-
nostic test (RDT) or microscopy, has been an essential
component of the World Health Organization’s (WHO)
guidelines for malaria control [1, 2]. RDTs are preferable
in primary healthcare facilities (PHFs) and community set-
tings with limited resources, because unlike microscopy,
they are easy-to-use, not time-consuming, and do not
require electricity [1]. These advantages mean that RDTs
are used in 43 out of 45 African countries in which mal-
aria is endemic [3]. The test-oriented prescribing practice
will allow the prevention of not only the wastage of the
more efficient but more expensive artemisinin-based com-
bination therapy (ACT) but also of the development of
malaria parasite strains, which are resistant to the therapy.
In reality, malaria over-diagnosis and misdiagnosis
have continued to be recognized problems in malaria-
endemic countries in Africa and Asia [4], and healthcare
workers (HWs) at PHFs have continued prescribing anti-
malarial drugs without positive test results. Several
studies have reported that fewer than 50% of HWs adhere
to negative RDT results [5–8], although the rate of pre-
scribing antimalarial drug for test-negative cases varies
widely (19.0–99.9%) [9]. To benefit from the improved
cost-effectiveness of more accurate diagnosis, we need a
better understanding of why this over-prescribing behav-
ior occurs.
Unlike in other malaria-endemic countries in Africa,
in Madagascar, medical doctors play a principal role in
the routine clinical work at PHFs. We previously re-
ported that > 80% of HWs prescribe antimalarial drugs
in case of negative test results in Madagascar and that
more frequent supervision and experience of frequent
RDT positive results in HWs practice have increased
their National Malaria Program (NMP) adherence [10].
However, we do not have sufficient knowledge about why
and how HWs at PHFs in malaria-endemic regions make
treatment decisions for test-negative cases. A qualitative
approach can allow us to better understand the perspec-
tive of HWs, using which HWs make certain treatment
decisions that were not known in previous quantitative
studies.
In this qualitative study, we aimed to understand why
and how HWs in Madagascar prescribe antimalarial
drugs despite negative test results. After gaining more
insight into the practice perspectives of these HWs, we
then aimed to explore how protocols can be developed
for antimalarial drug use and educational programs to
promote correct prescribing habits.
Methods
Study setting
This study was conducted at regional PHFs in Toliara, the
capital of the Atsimo-Andrefana region of Madagascar.
This region is characterized as semi-arid with short, occa-
sional, and epidemic-like malaria transmission [11]. The
proportion of malaria positive using RDT was 2.4% in this
region in 2011 [12].
PHFs are the smallest healthcare system in which
qualified HWs (i.e., medical doctors, nurses, or mid-
wives) work in Madagascar. In general, a medical doctor
is engaged in routine clinical work as a principal pre-
scriber at PHFs. Health services related to malaria are
mainly provided at PHFs by HWs, but they only received
outpatients, and patients who need hospitalization are
referred to district hospitals.
The District Health Service (DHS) works in collabor-
ation with PHFs to supervise malaria treatment pro-
grams and support HWs by giving explanations, praise,
or remarks and by updating knowledge. Some HWs at
PHFs in the region where this study was conducted
received training by the DHS in 2007. Since then, sup-
plementary guidance about managing patients with
fevers has occasionally been given to HWs, in written or
verbal format, to improve the program. However, there
are other programs concerning malaria treatment in
Madagascar. In 2006, a separate malaria guideline was
launched as a part of the already established Integrated
Management of Childhood Illnesses (IMCI) program.
These programs not only provide training at medical
and nursing schools but also provide continued training
to HWs.
NMP in Madagascar
With some modification for national adaptation, the rec-
ommendation of World Health Organization for malaria
control [13] led to the development of the new NMP in
Madagascar. This program [14], which was launched in
2005, provided all PHFs with multiple strategies for mal-
aria treatment based on the assumption that RDTs are
widely available in Madagascar. Specifically, the NMP
guidance has recommended that all fever cases (i.e., >
37.5 °C) be tested by RDT or microscopy and that ther-
apy with antimalarials only be prescribed for patients
with positive RDT results. In our study setting, parasito-
logical confirmation of malaria was mandatory before
prescribing ACT, with the exception that parasite-based
diagnosis was not available.
ACT with artemisinin and amodiaquine was the main
approach authorized by the government for treating un-
complicated malaria. Artemisinin-lumefantrine was only
indicated if this first-line treatment failed. For severe
and/or complicated malaria, treatment with quinine in-
jection was recommended. In pregnancy, women who
were RDT-positive were prescribed quinine tablets,
whereas sulfadoxine-pyrimethamine (SP) was used as
intermittent preventive treatment. In the NMP, chloro-
quine is no longer used for malaria treatment and hence
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should be withdrawn from PHFs. The NMP has been offi-
cially updated in 2007 and 2013 [11, 15]; however, the
guideline on antimalarial use has not changed since 2005.
Availability of antimalarial drugs
In Madagascar, antimalarial drugs are readily available
outside governmental healthcare structures, including in
private pharmacies and local shops, or from private dona-
tions that are beyond governmental control. At the time
of the study, several medications were available both in re-
gional services and in private sectors: (1) artemisinin-
amodiaquine (government-authorized ACT) was mainly
available in PHFs, with limited availability in private facil-
ities; (2) other ACTs (e.g., artesunate-amodiaquine and
artemether-lumefantrine) were available at local pharma-
cies and from community HWs not in the public sector;
(3) SP was also available in both public and private health
sectors; (4) chloroquine, though officially withdrawn from
PHFs, was still available at some private healthcare facil-
ities, local pharmacies, and even local shops; (5) oral quin-
ine tablets were available for pregnant malaria clients in
PHFs; and (6) quinine injection was available for severe
and complicated malaria in PHFs. Prescribers were free to
determine which specific antimalarial drugs to use per
case from these options.
The availability of antimalarial drugs has not changed.
The latest report of a nationwide study has shown that
antimalarials, such as quinine, chloroquine, amodia-
quine, and SP, continued to be used, particularly for chil-
dren aged < 5 years with fever and that the amount of
conventional antimalarial use exceeded that of ACTs in
2016 [16].
Data collection
As we previously reported, 82% (63/77) HWs declared
that they prescribed antimalarial drugs in case of RDT
negative in the study region [10]. From these 63 HWs,
we purposively selected 14 medical doctors and 2 nurses
from 11 PHFs. Among the 16 participants, 10 were
males. All HWs from private health centers were med-
ical doctors, but from public PHFs, six were medical
doctors and two were nurses. Concerning experience, 12
HWs had been qualified for more than 5 years, and only
5 of these had received official training about the NMP
(Table 1).
The first author (DHR) visited the PHF settings twice,
once in December 2008 and once in October 2009, ap-
proximately 3–4 years after the NMP had been intro-
duced. DHR is a native speaker of the language used in
the interviews. Interviews lasted 20–45 min per partici-
pant. The following open-ended questions with follow-
up probe questions were used: (1) Why do you prescribe
antimalarial for clients without positive RDT results?
and (2) How can you prescribe an antimalarial to clients
who did not test positive? All interviews were recorded
with a digital recorder, transferred to a laptop immedi-
ately after the interview, and transcribed within a few
days. During the second visit, additional interviews were
conducted to gain answers to the questions emerged
from the first coding series. Collected data were man-
aged, coded, and categorized in the same way.
Data analysis
Shortly after the initial visits, the first five interviews
were translated into English and coded cyclically by the
authors until consistent categories emerged. Those cat-
egories were then grouped into themes. When a new
theme emerged that was not compatible with existing
themes, we created a new one. We continued with the
same approach until all data were coded and collated
into several themes. We adopted the coding method
developed by James Spradley using four analytical proce-
dures: domain analysis, structural analysis, taxonomic
analysis, and componential analysis [17]. DHR conducted
Table 1 Characteristics of healthcare workers
Variables Frequency
N (%)
Age (completed years)
31–40 8 (50)
41–50 5 (31.3)
51–60 3 (18.7)
Sex
Male 10 (62.5)
Female 6 (37.5)
Qualification
Doctor 14 (87.5)
Nurse 2 (12.5)
Type of workplace
Public primary health center 8 (50)
Private primary health center 8 (50)
Trained on malaria program/RDT
Yes 5 (31.3)
No 11 (68.7)
Number of years from graduation
1–5 4 (25)
6–10 6 (37.5)
11–15 2 (12.5)
> 15 4 (25)
Number of years at the current position
1–2 5 (31.3)
3–5 8 (50)
> 5 3 (18.7)
RDT malaria rapid diagnostic test
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initial coding, and all authors were involved in the subse-
quent coding procedures. All codes, categories, and
themes were written in English. To ensure confirmability
and dependability of our findings [18], all authors regu-
larly met and checked the analyses for consistency and
conceptual development as the coding progressed. If there
was any disagreement on the analyses, we discussed the
matter until we could reach consensus. Furthermore,
DHR presented the findings to some interviewees at
the second visits to gain credibility. Finally, we tried
our best to include the context of NMP practice in
Madagascar, which would help the findings to have
transferability.
Results
Three themes emerged around the issues of HW non-
adherence to the NMP guideline on antimalarial drug
use: “HW’s faith to give top priority to clients,” “avail-
ability of alternative ways to procure antimalarial drugs,”
and “careful selection of patients with an indication of
antimalarial treatment by HWs.” Each category in the
three themes was shown in the Fig. 1.
HW’s faith to give top priority to clients
There were multiple reasons, depending on the individ-
ual context for the prescribers, for why HWs prescribed
antimalarial drugs despite the lack of positive RDT re-
sults. They firmly believed that they gave the highest pri-
ority to clients.
Helping clients as the main purpose of practice
HWs considered that their primary duty as a practi-
tioner was to alleviate clients’ suffering and to heal them.
They cited that it was their top priority to deliver the best
care to their clients in front of them, even if this meant
prescribing antimalarial drugs without positive results, be-
cause it was the fastest way for clients to recover.
What I’m doing here [for RDT-negative patients], for
example a [febrile] child without other obvious cause,
I prescribe alternative ACT because I cannot use the
government ACT for this case. I tell the mother to
come again the next day or something like that, her
child is healed, her child is on form, complaints
disappeared. What we are searching for is clients’
well-being, isn’t it? (HW 6)
This recognition of duty was considered a principle for
all clients, but HWs did comment that private clients or
their own relatives received priority and were more
frequently treated with antimalarial drugs.
It was the case of my child, my own child, this RDT-
negative result happened to him so I did not give
antimalarial first but his illness really got worse. I did
not support his complaints. Finally, I gave him
antimalarials, and he was healed almost right afterward!
(HW 5)
For my private clients and even more for my own
child, I will not hide from you, I prescribe alternative
ACTs even when RDT is negative. (HW 3)
It was also noted that missing cases of malaria may
have serious implications for their clients’ health and
work. Therefore, prescribing antimalarial drugs based on
symptoms was considered the only correct option. If
antimalarial drugs were not prescribed, unsatisfied cli-
ents may come back many times, complaining about
their disease:
I continue to prescribe antimalarial drugs [even with
negative RDT]. Even if test result is negative I think
it may be malaria and then I will prescribe quinine…
You know, I’m worried that if the client is not healed
soon he might be laid off by his boss… if he is not
healed he should come back again and his boss will
say why he should go back many times there? ‘What
are you still doing there?’… Do you understand what
I mean? (HW 11)
Fig. 1 Reasons of antimalarial prescription when malaria testing is negative
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We know what is best
HWs said that the final decision to prescribe an antimal-
arial drug, like any other prescription, rested on them,
irrespective of what standardized guidelines or other au-
thorities said. HWs reluctantly and partially followed the
guideline that they perceived as a top-down order due to
the requests from the Ministry of Health as well as occa-
sional tough enforcement exercised by the regional mal-
aria staff.
That’s clear, it’s just an order … before I denied [the
recommendation] because I was not convinced, but a
regional malaria staff member came here, … she
‘shouted to me’, that is the right word ‘she shouted to
me’...it’s somehow like we do not have right to
understand …I asked an explanation and I got this
[showing a note from the Ministry of Health]. (HW 9)
It’s curious that it seems that we (doctors) are the
worst among educated people, we repeat only what is
written in this book [NMP], we are not reasoning at
all but following only what is said to do but there are
something on which we should use our brain, for this
case we should do this, for another case we should do
this but not following only what is said inside this
book. (HW 5)
Only prescribers had the individualized, detailed infor-
mation about the lives of each client; put simply, it was
claimed that they only knew the client’s perception of
the disease and their real need. Indeed, treatment deci-
sions were context-bound, with HWs deciding the treat-
ment appropriateness on a case-by-case basis. HWs
perceived that official guidelines failed to allow for this
reality of practice:
They [malaria program staff] implement policy, which is
their work; we are technicians, we are using techniques
[meaning that whatever policy requests, only the
prescribers find what is good for clients]. (HW 7)
Clients often presented after self-treatment with an
unknown dose of an unknown antimalarial drug for un-
known durations, then HWs would question the reliabil-
ity of RDT-negative results. Moreover, given the limited
possibility of optimal follow-up, once the client went
home, HWs wondered whether or not treating test-
negative clients was truly safe. In such situations where
healthcare was not performed in an ideal way, the HWs
believed that only they could evaluate the individual
needs of each client. The HWs’ concern about missing
cases of malaria, which may quickly become compli-
cated, pushed them to favor prescribing antimalarial
drugs before the disease “opens out” (HW 12)
Experiential conviction
Antimalarial use was also justified based on accumu-
lated, successful experiences in their career. For HWs,
prescribing an antimalarial has been the most commonly
used and most successful way to manage cases of fever.
One HW stated:
Since I started working, presumptive diagnosis alone
has been used, and I see that this way to diagnose has
been good for clients. (HW 5)
HWs also believed in other advantages of antimalarial
drugs, like the anti-inflammatory and antipyretic effects,
which they had learned from their own experience or
from colleagues. It was reported that a less-than-standard
dose of quinine was prescribed for this purpose:
“For this matter, the reason I prescribe antimalarial
drugs…when it [RDT] is negative I don’t think any
more to malaria but I use it for the anti-inflammatory
effect of quinine because I heard that, so the reason I
prescribe it [quinine] was to reduce quickly the fever
but not for malaria… that is my idea.” (HW 14)
“I want to mention one more thing about the reason
of using quinine. We have quinine in stock, and they
are there to be used, if we don’t use them, they will
just reach their expiration date, so I use them because
of their anti-inflammatory effects.” (HW 15)
Availability of alternative ways to procure antimalarials
No HWs reported the use of government-approved
ACT (artemisinin-amodiaquine) without a positive RDT
result because medical records of government-approved
ACT prescriptions and RDT test results performed at
their PHFs were strictly monitored by DHS. However,
regardless of whether HWs were working at private or
public PHFs, they could prescribe antimalarial drugs
both inside and outside their workplace. For example, it
is possible to obtain antimalarial drugs outside PHFs,
particularly at local pharmacies, where prescribers from
PHFs can send their clients to procure alternative anti-
malarial drugs.
Using non-governmental drugs
It is not rare for HWs to prescribe ACTs like artemether-
lumefantrine or artesunate-amodiaquine for clients who
tested negative. For these ACTs, there is no explicit re-
striction on their use in the NMP. HWs prescribed them
because “Not explicitly forbidden’ means it is allowed to
use, doesn’t it?” (HW 12)
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Using less monitored drugs
Several antimalarial drugs, other than the approved ACT
combination, were stored under different levels of strict-
ness but were still available. For example, although both
SP and quinine tablets were supplied to PHFs on the
basis that they would be used for pregnant women,
HWs could order and stock more numbers of these
drugs than those expected for practical use because the
status of supply and use of these drugs was not strictly
monitored. The remaining antimalarial drugs could eas-
ily be used in place of ACTs if patients had a negative
test result. A HW said “These antimalarial drugs were
for what if not clients?” (HW 15) when referring to the
large stock available at hand. Some HWs continued to
prescribe SP or quinine outside their indications, but
others started to partially follow the indications set out
by the NMP.
… SP is available but we do not use them. SPs are for
pregnant women only. We do not use them for
patients. (HW 3)
As for SPs, I do not use them for curative treatment.
They are only for pregnant women. I do not use
them. (HW 6)
That is the rule already set out; every time RDT is not
positive, there should not be any more antimalarial
prescription, neither SP nor quinine, that is the rule.
For us, SPs are only for women attending antenatal
visits, but I prescribe some [for my patients]. (HW 15)
Careful selection of patients with an indication of
antimalarial treatment by HWs
HWs did not prescribe antimalarial drugs to everyone
with negative test results. Prescribing antimalarials for
RDT-negative patients was not just a way to simplify
their job. Rather, there was a specific population for
whom they chose to prescribe antimalarials. Each pre-
scriber had accumulated experience on the use of anti-
malarial drugs and carefully chose what to prescribe
according to the client’s need, including consideration of
the client’s physical condition, preference, and economic
status.
Causes of fever excluded
HWs employed standard diagnostic reasoning to decide
what antimalarial to prescribe, and how and when a cli-
ent presents with fever. This included collecting infor-
mation, considering test results, and deciding whether
guideline criteria were met. When only “isolated fever”
was found, or when febrile clients had typical signs of
malaria (e.g., headache, vomiting, shivering), HWs often
prescribed antimalarial drugs. By contrast, most HWs
did not prescribe antimalarial drugs when the test results
were negative and there were other symptoms like
cough, rhinorrhea, or pharyngitis:
My decision [to prescribe antimalarial drugs or not] is
based on symptoms. Particularly, when I don’t find
any other explanations for fever, I prefer to consider
that malaria may be there. For me, the priority is
clients’ well-being: Does the child cough? No! Does
the child have diarrhea? No! There is no identifiable
cause for fever, but RDT is negative… then I may
prescribe antimalarials. (HW 13)
Every time I see a case of fever with backache and
something like that… I think I go directly to [the
diagnosis of] malaria [and prescribe antimalarial
drugs]. (HW 11)
The clients’ temperature also affected the choice of anti-
malarial. Oral medications (e.g., SP tablets, quinine tablets,
and chloroquine tablets or syrup) were prescribed when
the clinical situation was considered less risky (i.e., lower
temperatures). However, when there appeared to be a se-
vere disease, with a temperature around 40 °C, the paren-
teral route (quinine injection) was preferred. Oral tablets
were also converted to parenteral injections if the re-
sponse to oral therapy was poor. In addition, client prefer-
ence for injection or oral tablets influenced the HWs
choice of route for quinine administration.
Looking at specifics
Treatment history influenced antimalarial drug prescrib-
ing, with or without antibiotics. HWs stated that they
may use antimalarial drugs despite a negative RDT result
if a client has persistent fever despite previous treatment
with antibiotics. In contrast, patients’ failure to recover
with antimalarial alone eventually leads to the addition
of antibiotics. They also reported that a recent trip to a
high-endemic region would increase the likelihood of
prescribing an antimalarial. Many children were also
given antimalarial drugs despite negative test results:
We practice according to each case … for children
with fever, I prescribe antimalarial drugs … that’s why
I said “according to each case” … if clients have signs
of sore throat, I don’t prescribe [antimalarial drugs].
(HW 07)
By contrast, where there was a regular and continuous
use of insecticide-treated bed nets, this limited antimal-
arial prescribing. Other test results (e.g., microscopy,
Widal test for typhoid fever) were also used to inform
antimalarial prescribing practices, and the adverse effects
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of antimalarial drugs were of serious concern to the
HWs. For example, more frequent side effects and in-
tolerance were reported with amodiaquine-based ACTs
compared with the other medications. Finally, HWs also
considered a client’s economic status, specifically pre-
scribing ACTs sold at very reasonable prices through so-
cial marketing if clients had a poor economic status; the
more expensive ACTs (e.g., artemisinin-lumefantrine)
were only prescribed for those who could afford them.
Thus, HWs took multiple client factors into consider-
ation when determining what to prescribe.
Discussion
In this study, we examined why and how HWs in PHFs
did not adhere to the national prescribing guideline set
out by the NMP. The reasons for non-compliance with
the guideline can be categorized into prioritizing client
beneficence, clinician independence for prescriptions,
and belief in the effectiveness of antimalarial drugs. In
case of negative RDT results, both clinical and non-
clinical factors influenced case and antimalarial drug se-
lections. This study highlights issues in translating na-
tional policy into individual clinical practice and
emphasizes the need to develop a policy that is congru-
ent to the mindsets and working contexts of practi-
tioners for effective policy implementation. This is one
of the first attempts to elucidate the experience of pre-
scribers that mostly comprised physicians, unlike some
other studies in which non-physician prescribers were
interviewed [19, 20].
HWs justified their prescribing behavior by clinician
autonomy based on the ethical principle of client benefi-
cence. Antimalarial drugs were used to reinforce their
belief that this was appropriate. HWs considered that
clinician independence had priority over national policy
with respect to client beneficence. A review of clinicians
in developed countries indicated that one third consid-
ered that guidelines reduced their autonomy and over-
simplified medicine [21]. The belief that clinicians
should retain independence could be a potential barrier
to guideline adherence. It is important for policymakers
to consider and emphasize such clinical perspective
when defining the efficacy, effectiveness, and efficiency
of RDT-based diagnosis and treatment. This relationship
between clinician autonomy and over-prescription has
rarely been explored in previous literature; in contrast,
reports have revealed that clinicians are more passive,
being influenced by patient preference, peer pressure,
and fear of misdiagnosis [19].
The concept of evidence-based guidelines for clinical
practice was originally advocated for informed patient
decision-making and rational social judgments, where
practical guideline was defined as “systematically developed
statements to assist practitioner and patient decisions about
appropriate health care for specific clinical circumstances”
[22]. Our study revealed that policy administrators urged
HWs to adhere the national policy without a detailed
explanation of its concept and objective to HWs. Clinicians,
policy administrators, and policymakers should have a con-
sensus through dialog that the national policy and guide-
lines also have every respect for client beneficence. Further,
to avoid conflict between clinician independence and guide-
lines, policymakers should take care to distinguish the
scope of a guideline and the range of discretionary deci-
sions available to the clinicians. Past experience of antimal-
arial use before RDTs has led to strong beliefs in the
continued use of the drug among HWs. This is consistent
with the results from other studies [23, 24]. Additional be-
liefs about the drug benefits, including anti-inflammatory
and antipyretic effects, justified their continued use. The
origin of this belief was unclear, but it seemed to be
strengthened by the shared experience.
Although low clinical risk has been demonstrated when
not prescribing antimalarial drugs for test-negative cases
[25], not offering malaria treatment for false-negative
cases might also be inappropriate because the conversion
rate from negative to positive RDT can be high [26]. The
effectiveness of the RDT-based strategy is sensitive to mal-
aria endemicity [27]. Consequently, letting HWs know of
the endemicity in the region may be an important strat-
egy. The issue is even more important as malaria inci-
dence is dramatically decreasing during the last 10 years
in many parts of the world including Madagascar, and less
febrile illnesses are due to malaria [3].
According to the interviewees, there remains a large
antimalarial stock in health facilities, and different types of
antimalarials, including non-governmental ACTs, are eas-
ily available outside health facilities. Addressing the con-
trol of antimalarials both inside and outside PHFs should
be a priority if the goal of limiting excess antimalarial use
is to be realized. Ideally, all medications should be closely
monitored at both PHF and pharmacy levels. Accurate in-
formation about the numbers of pregnant women ex-
pected to attend PHFs should also be monitored to ensure
adequate, but not excessive, supplies of SP. Especially, it
may be difficult to control antimalarial drugs at private
PHFs, and it remains a significant issue.
It may be important that HWs receive further training
about the characteristics of non-malarial illnesses, other
available tests, correct and updated information on mal-
aria epidemiology, and possible harms of using non-ACTs,
in addition to the NMP protocol. Understanding and
anticipating the course of non-malarial febrile illnesses
could reassure HWs that it is appropriate not to give anti-
malarials. Additional education on other available tests,
such as full blood count, C-reactive protein, urine strip
test, and/or Widal reaction, or at least teaching regular
diagnostic assessment process, should also be helpful. It
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should also be educated that the incidence of malaria has
been decreasing in Madagascar [16]. Therefore, HWs
need to be kept informed so that they can have realistic
expectations of the possibility of a febrile patient having
malaria.
Lastly, it may also be important that policymakers more
clearly understand the clinicians’ perspective, appreciating
their willingness to provide best possible care for individ-
ual patients that they handle. By mutually understanding
each other’s perspective, a good balance can be achieved
between individual benefits and those of the society.
We identified the limitations of this study. First, this
study has been conducted in a specific setting with one
defined malaria strata in Madagascar. Therefore, the
generalization of the findings of this study to other
malaria-endemic settings is limited. Second, our inter-
pretation was derived from the analysis of translated
transcripts, with possible loss of specific cultural mean-
ings and nuances. However, the fact that interviews were
conducted, transcribed, and translated by the first author
who is a native speaker of the language used during in-
terviews and that regular discussions were conducted
between coauthors throughout the study may limit such
a loss. Third, our study did not focus on the interaction
between clinicians and patients. There may be a tension
between HWs and patients which can influence HWs’
prescribing behavior. Further study on the interaction
between HWs and patients including interviews from
patients is necessary. Fourth, HWs may have changed
the prescribing behavior for RDT-negative cases since
this study was conducted in 2008–2009. Though the lat-
est formal information on prescribing behavior related
to RDT results in the study site was not available, a recent
study in Madagascar pointed out HWs’ lack of trust on
RDT results and prescribing quinine for RDT-negative pa-
tients [28]. To update our knowledge, an evaluation on
the current HWs’ adherence to RDT results is needed. Fi-
nally, this study did not explore HWs’ behavior when they
prescribed concomitantly antimalarial and antibiotic for
fear of insufficient treatment. It would be useful to further
investigate whether such behavior and perception is the
reason for over-prescription.
Conclusions
Although the guidelines by the WHO and NMP require
that only RDT results inform antimalarial prescriptions,
complete adherence is difficult to achieve in Madagas-
car’s primary care context for of a multitude of factors.
Notable among these is the basic tension between the
HWs autonomy for clinical practice versus the adher-
ence to national policy. However, justification based on
client beneficence was compounded by the fact that
antimalarial procurement was relatively easy in most sit-
uations, indicating that efforts to modify both factors are
needed if WHO and NMP guidance is to be realized. In-
terventions may include giving more information to
HWs, educating HWs, limiting the availability of anti-
malarial drugs, monitoring the prescribing of antimalar-
ials more closely, and ensuring consistency among the
different guidelines. Practitioners rightly place the safety
of the patient in front of them as their top priority;
therefore, guidelines need to be tailored to the contexts
in which they will be delivered, taking care to ensure
that the concerns of practitioners are addressed.
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